Kezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fibrosis Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Wednesday, March 9, 2022, at 2:10 p.m. ET. A live webcast of the panel will be

Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of strategic business development executive Courtney Wallace to its Board of Directors. “We are excited to welcome Courtney to our Board during an important time in Kezar's continued evolution,” said Jean-Pierre Sommadossi, Ph.D., Chair of the B

Kezar Appoints Courtney Wallace to its Board of Directors

The company reported promising results from a phase 2 study.

Why Kezar Life Sciences Stock Is Soaring Today

The stock price of Kezar Life Sciences Inc (NASDAQ: KZR) increased by over 55% pre-market today. This is why it happened.

Kezar Life Sciences (KZR) Stock: Why The Price Surged Today

Kezar Life Sciences, Inc. (NASDAQ: KZR) shares are soaring Tuesday following a positive clinical readout. What Happened: California-based Kezar announced positive interim results from the Phase 2 portion of the MISSION clinical study evaluating KZR-616 in patients with lupus nephritis.

Small-cap Biopharma Kezar Life Sciences Is Soaring, Here's Why

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN). “The MISSION Phase 2 interim results present a strong s

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST. A webcast of the event may be accessed at the “Events &a

Kezar Life Sciences to Present at the Jefferies London Healthcare Conference

ALEXANDRIA, Va. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.

Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. “Excellent progress continues across our programs, as we reached target enrollment in both of our Phase 2 trials with KZR-616 and announced our first patient dosed

Kezar Reports Third Quarter Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET. The event will highlight KZR-616, including interim data from Kezar's MISSION study, an open-label Phase 2 trial in patients with active, proliferative lupus nephritis a

Kezar to Host Virtual Investor and Analyst Day on November 15, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the first patient has been dosed in KZR-261-101, a Phase 1 clinical trial evaluating KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon. “Dosing the first patient with KZR-261, the

Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs. As a member of the management team and executive committee, Ms. Jain will lead Kezar's overall investor relations, public relations, and scientific communications effo

Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM) completed the target enrollment of 24 subjects. PRESIDIO is a Phase 2 randomized, placebo-controlled, crosso

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2021 financial results and corporate highlights. “We were pleased this quarter to share the final data update from our completed Phase 1b portion of the MISSION study, building on the positive safety, tolerability and early efficacy profile

Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the “Novel Targets for Autoimmune Diseases” panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET. A live webcast of the panel

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee. Comprised of thought leaders in immunology, rheumatology, neurology, and nephrology, members of the committee will provide Kezar with strategic guidance and external perspective regarding the clinical developmen

Kezar Life Sciences Announces Formation of Clinical Advisory Committee

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented b

Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors. “Micki's addition to the board is instrumental as we continue to evaluate the broad therapeutic potential of Kezar's lead program to treat a number of immune-mediated diseases,” said Jean-Pierre

Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET. A live webcast of the fireside chat may be accessed at the “Events & Presentations” secti

Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a MISSION Phase 1b data update call for investors and analysts during the European Congress of Rheumatology (EULAR 2021) on Wednesday, June 2, 2021 at 4:30 p.m. ET. The event will highlight final data from Kezar's MISSION Phase 1b trial, the 2

Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its first quarter 2021 financial results and corporate highlights. “Last quarter saw excellent execution by the Kezar team across both of our programs. We look forward to sharing data this June from the completed Phase 1b portion of the MISSION study of KZR-616

Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, has been recognized as a winner of the 2021 Bay Area Best Places to Work, an awards program presented by the San Francisco Business Times and the Silicon Valley Business Journal. Select employers from the Bay Area were named winners of the award on May 7, 2021. These winning o

Kezar Life Sciences Recognized as 2021 Bay Area Best Places to Work

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today presented preclinical data on the company's novel protein secretion program during two poster sessions at the American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting. “The growing body of evidence generated by our team supports the strong therapeutic poten

Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its fourth quarter and year end 2020 financial results and corporate highlights. “Despite unprecedented circumstances, 2020 was a year of significant corporate and clinical accomplishments, thanks to the excellent execution by the Kezar team,” said John Fowler,

Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in the “Autoimmune/Complement” panel discussion at the Cowen 41st Annual Virtual Health Care Conference on Wednesday, March 3, 2021 at 11:40am EST. The panel discussion will be available to live conferen

News for Kezar Life Sciences Inc Stock (KZR)